Angiotensin II Type 2 Receptor: A Target for Protection Against Various Disease conditions

Pharmacology

The renin-angiotensin system's protective arm contains the angiotensin AT2 receptor (AT2R), which was first identified more than 30 years ago. Since its discovery, the AT2R has grown from a binding site with unknown function to a firmly established major effector that is a target for emerging medications. In most preclinical models, the AT2R represents an endogenous protective mechanism that can be altered to treat cancer, as well as lung, renal, cardiovascular, metabolic, cutaneous, and neurological illnesses. This page offers a thorough discussion of what we now know about the AT2R, including its discovery, location within the RAS, and general functions. The properties of the AT2R, including its structure, intracellular signaling, homo- and heterodimerization, and expression, are then thoroughly examined. We describe AT2R-selective ligands, ranging from naturally occurring peptides to synthetic peptides and nonpeptide compounds utilized as research tools. We conclude by outlining the AT2R's numerous protective effects in numerous experimental disease models, its known physiological roles, and the AT2R ligands that are currently being developed for clinical use. The current review highlights the contentious issues and knowledge gaps surrounding this receptor and sheds light on potential directions for AT2R research in the future.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.